TR201909072T4 - Fosforilkoline karşı yeni antikorlar. - Google Patents
Fosforilkoline karşı yeni antikorlar. Download PDFInfo
- Publication number
- TR201909072T4 TR201909072T4 TR2019/09072T TR201909072T TR201909072T4 TR 201909072 T4 TR201909072 T4 TR 201909072T4 TR 2019/09072 T TR2019/09072 T TR 2019/09072T TR 201909072 T TR201909072 T TR 201909072T TR 201909072 T4 TR201909072 T4 TR 201909072T4
- Authority
- TR
- Turkey
- Prior art keywords
- sequence
- amino acid
- seq
- acid sequence
- identity
- Prior art date
Links
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 title abstract 3
- 229950004354 phosphorylcholine Drugs 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 1
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 abstract 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 1
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 1
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
Mevcut buluş, fosforilkolin ve/veya bir fosforilkolin konjugatına bağlanabilen bir antikor veya antikor parçası ile ilgilidir, burada antikor veya antikor parçası bir değişken ağır zincir (VH) bölgesi ve/veya bir değişken hafif zincir (VL) bölgesini içerir ve burada - (a) bir VH bölgesi, şunlardan oluşan bir gruptan seçilen bir, iki veya üç tamamlayıcılık belirleme bölgesini (CDR'ler) içeren bir amino asit dizisini içerir: SEK KİM NO: 17'nin dizisi ile en az %25, %50, %75 veya %100 dizi aynılığına sahip bir amino asit dizisini içeren bir CDR1 dizisi; SEK KİM NO: 18'in dizisi ile en az %5, %11, %17, %23, %29, %35, %47, %52, %58, %64, %70, %76, %82, %94 veya %100 dizi aynılığına sahip bir amino asit dizisini içeren bir CDR2 dizisini ve SEK KİM NO: 19, 20, 21 veya 22'nin dizisi ile en az %4, %9, %13, %18, %22, %27, %31, %36, %40, %45, %50, %54, %59, %63, %68, %72, %77, %81, %86, %90, %95 veya %100 dizi aynılığına sahip bir amino asit dizisini içeren bir CDR3 dizisi ve/veya (b) bir VL bölgesi, şunlardan oluşan gruptan seçilen bir, iki veya üç tamamlayıcılık belirleme bölgesini (CDR'ler) içeren bir amino asit ¬dizisini içerir: SEK KİM NO: 23 veya 24'ün dizisi ile en az %5, %11, %17, %23, %29, %35, %47, %52, %58, %64, %70, %76, %82, %94 veya %100 dizi aynılığına ¬sahip bir amino asit dizisini içeren bir CDR4 dizisi; SEK KİM NO: 25'in dizisi ile en az %14, %28, %42, %57, %71, %85 veya %100 dizi aynılığına sahip bir amino asit dizisini içeren bir CDR5 dizisi; SEK KİM NO: 26'nın dizisi ile en az %11, %22, %33, %44, %55, %66, %77, %88 veya %100 dizi aynılığına sahip bir amino asit dizisini içeren bir CDR6 dizisi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161521593P | 2011-08-09 | 2011-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201909072T4 true TR201909072T4 (tr) | 2019-08-21 |
Family
ID=46679261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/09072T TR201909072T4 (tr) | 2011-08-09 | 2012-08-08 | Fosforilkoline karşı yeni antikorlar. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9803028B2 (tr) |
| EP (1) | EP2742068B1 (tr) |
| JP (1) | JP6277125B2 (tr) |
| KR (1) | KR101947758B1 (tr) |
| CN (1) | CN104039832B (tr) |
| AR (1) | AR087485A1 (tr) |
| AU (1) | AU2012293646B2 (tr) |
| BR (1) | BR112014002929A8 (tr) |
| CA (1) | CA2843921A1 (tr) |
| CY (1) | CY1121950T1 (tr) |
| DK (1) | DK2742068T3 (tr) |
| ES (1) | ES2732838T3 (tr) |
| HK (1) | HK1200852A1 (tr) |
| HR (1) | HRP20190988T1 (tr) |
| HU (1) | HUE045163T2 (tr) |
| LT (1) | LT2742068T (tr) |
| MX (1) | MX364425B (tr) |
| PL (1) | PL2742068T3 (tr) |
| PT (1) | PT2742068T (tr) |
| RS (1) | RS58986B1 (tr) |
| RU (1) | RU2654584C2 (tr) |
| SG (1) | SG2014009344A (tr) |
| SI (1) | SI2742068T1 (tr) |
| TR (1) | TR201909072T4 (tr) |
| TW (1) | TWI707873B (tr) |
| WO (1) | WO2013020995A1 (tr) |
| ZA (1) | ZA201400665B (tr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6277125B2 (ja) * | 2011-08-09 | 2018-02-07 | アセラ・バイオテクノロジーズ・アーベー | ホスホリルコリンに対する新規抗体 |
| JP6277126B2 (ja) | 2011-08-09 | 2018-02-07 | アセラ・バイオテクノロジーズ・アーベー | ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体 |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| CA2979361A1 (en) | 2015-03-09 | 2016-09-15 | Caris Science, Inc. | Method of preparing oligonucleotide libraries |
| EP3314027A4 (en) | 2015-06-29 | 2019-07-03 | Caris Science, Inc. | THERAPEUTIC OLIGONUCLEOTIDES |
| US10941176B2 (en) | 2015-07-28 | 2021-03-09 | Caris Science, Inc. | Therapeutic oligonucleotides |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2402664A1 (fr) | 1977-09-07 | 1979-04-06 | Agronomique Inst Nat Rech | Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications |
| US5955584A (en) | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| EP0257778B1 (en) | 1986-08-06 | 1995-03-22 | Scripps Clinic And Research Foundation | Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas |
| JPH02188532A (ja) | 1989-01-17 | 1990-07-24 | Otsuka Pharmaceut Co Ltd | リポソームワクチン |
| AU5522390A (en) | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids |
| JP3283041B2 (ja) | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
| AU666473B2 (en) | 1990-12-10 | 1996-02-15 | Entremed, Inc | A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis |
| RU2014609C1 (ru) * | 1991-06-06 | 1994-06-15 | Московский институт тонкой химической технологии им.М.В.Ломоносова | Способ определения белков, специфичных к фосфорилхолину |
| WO1993018161A1 (en) | 1992-03-03 | 1993-09-16 | The Rockefeller University | Receptor complexes with b29 (ig-beta or ig-gamma) and their uses |
| AU5959494A (en) | 1992-12-29 | 1994-07-19 | Entremed, Inc | Vaccines against sterols |
| EP0684814B1 (en) | 1993-02-22 | 1998-06-17 | Alza Corporation | Compositions for oral delivery of active agents |
| US5455032A (en) | 1993-07-29 | 1995-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Use of phosphocholine hapten conjugates in vaccines |
| US6375925B1 (en) | 1996-11-08 | 2002-04-23 | The Regents Of The University Of California | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| AU1159497A (en) | 1996-11-08 | 1998-06-03 | Regents Of The University Of California, The | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| US6225070B1 (en) | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
| US20040185039A1 (en) | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
| US6300308B1 (en) | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| WO2000002046A1 (en) | 1998-07-03 | 2000-01-13 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| AU773370B2 (en) | 1999-10-26 | 2004-05-20 | Regents Of The University Of California, The | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| SE0000855D0 (sv) | 2000-03-15 | 2000-03-15 | Karolinska Innovations Ab | Antigenic composition useful as a vaccine against atherosclerosis |
| AU2001259730A1 (en) | 2000-05-12 | 2001-11-26 | The Regents Of The University Of California | Standardized oxidized ldl assay |
| DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| US20070122419A1 (en) | 2003-04-11 | 2007-05-31 | The Regents Of The University Of California | Methods and compositions for treating atherosclerosis |
| CA2562550C (en) | 2004-04-15 | 2013-09-24 | Athera Biotechnologies Ab | Phosphorylcholine conjugates and corresponding antibodies |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| TW200726479A (en) * | 2005-04-12 | 2007-07-16 | Univ Duke | Method of inducing neutralizing antibodies to human immunodeficiency virus |
| AU2006330807A1 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of HMBG1 and/or rage and methods of use thereof |
| US20090258005A1 (en) | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
| JP5122908B2 (ja) | 2007-10-17 | 2013-01-16 | 日泉化学株式会社 | 自動車の内装用部材の取り付け構造 |
| US20110206679A1 (en) | 2008-07-07 | 2011-08-25 | Athera Biotechnologies Ab | New Therapeutic and Diagnostic Methods for Alzheimer's Disease |
| WO2012010291A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| CN105713092B (zh) * | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| JP6277125B2 (ja) * | 2011-08-09 | 2018-02-07 | アセラ・バイオテクノロジーズ・アーベー | ホスホリルコリンに対する新規抗体 |
| JP6277126B2 (ja) | 2011-08-09 | 2018-02-07 | アセラ・バイオテクノロジーズ・アーベー | ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体 |
-
2012
- 2012-08-08 JP JP2014524371A patent/JP6277125B2/ja not_active Expired - Fee Related
- 2012-08-08 AU AU2012293646A patent/AU2012293646B2/en not_active Ceased
- 2012-08-08 CN CN201280049552.0A patent/CN104039832B/zh not_active Expired - Fee Related
- 2012-08-08 TR TR2019/09072T patent/TR201909072T4/tr unknown
- 2012-08-08 TW TW101128575A patent/TWI707873B/zh not_active IP Right Cessation
- 2012-08-08 DK DK12747915.2T patent/DK2742068T3/da active
- 2012-08-08 KR KR1020147006274A patent/KR101947758B1/ko active IP Right Grant
- 2012-08-08 SG SG2014009344A patent/SG2014009344A/en unknown
- 2012-08-08 RS RS20190807A patent/RS58986B1/sr unknown
- 2012-08-08 PL PL12747915T patent/PL2742068T3/pl unknown
- 2012-08-08 CA CA2843921A patent/CA2843921A1/en not_active Abandoned
- 2012-08-08 WO PCT/EP2012/065505 patent/WO2013020995A1/en active Application Filing
- 2012-08-08 LT LTEP12747915.2T patent/LT2742068T/lt unknown
- 2012-08-08 RU RU2014108815A patent/RU2654584C2/ru active
- 2012-08-08 EP EP12747915.2A patent/EP2742068B1/en active Active
- 2012-08-08 AR ARP120102895A patent/AR087485A1/es unknown
- 2012-08-08 US US14/237,035 patent/US9803028B2/en active Active
- 2012-08-08 ES ES12747915T patent/ES2732838T3/es active Active
- 2012-08-08 SI SI201231604T patent/SI2742068T1/sl unknown
- 2012-08-08 BR BR112014002929A patent/BR112014002929A8/pt not_active Application Discontinuation
- 2012-08-08 HU HUE12747915A patent/HUE045163T2/hu unknown
- 2012-08-08 PT PT12747915T patent/PT2742068T/pt unknown
- 2012-08-08 MX MX2014001313A patent/MX364425B/es active IP Right Grant
-
2014
- 2014-01-28 ZA ZA2014/00665A patent/ZA201400665B/en unknown
-
2015
- 2015-02-05 HK HK15101305.1A patent/HK1200852A1/xx unknown
-
2017
- 2017-09-28 US US15/719,520 patent/US20180086848A1/en not_active Abandoned
-
2019
- 2019-05-30 HR HRP20190988TT patent/HRP20190988T1/hr unknown
- 2019-06-28 CY CY20191100683T patent/CY1121950T1/el unknown
-
2021
- 2021-04-13 US US17/229,837 patent/US20210238311A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201909072T4 (tr) | Fosforilkoline karşı yeni antikorlar. | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| NZ605980A (en) | Anti-fap antibodies and methods of use | |
| NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| TR201815254T4 (tr) | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari | |
| NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ595464A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
| IL299221A (en) | CD3 binding antibodies | |
| NZ601342A (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
| CA2818635C (en) | Antibodies selective for cells presenting erbb2 at high density | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| NZ712765A (en) | Antibodies that bind csf1r | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ726258A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| RS53819B1 (en) | ANTI-ACTIVIN ANTIBODIES AND THEIR APPLICATIONS | |
| NZ581512A (en) | Rsv-specific binding molecules and means for producing them | |
| RU2018140694A (ru) | ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА | |
| PH12014501783B1 (en) | Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody | |
| DOP2014000052A (es) | Anticuerpo anti-alfabeta tcr | |
| CY1121158T1 (el) | Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| RU2531523C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| RS53760B1 (en) | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES |